- Total of $6.7 million raised during current fiscal year through non-brokered private placements, including more than $1.1 million from insiders and employees
- Ortho-R designated as a Drug/Biologics combination product by the FDA
- Ortho-R Rotator Cuff tear repair program progressing towards start of US Phase I/II clinical study in early 2021
- Company’s shares started trading on the U.S. OTCQB under the symbol ORTIF.
MONTREAL, Dec. 18, 2020 /CNW/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (“Ortho RTI” or the “Company“), an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today reported its financial results and highlights for the third quarter of 2021 ended October 31, 2020.
“During the quarter, we continued making good progress on preparing our upcoming U.S. phase I / II clinical trial for rotator cuff tears repair. The IND preparation, cGMP…